Opinion|Videos|March 30, 2026
Interpreting FLAURA2 for Sequencing Strategies in in EGFR-Mutant NSCLC
Author(s)Heather Wakelee, MD, Helena A. Yu, MD
Heather Wakelee, MD, and Helena Yu, MD, examine how FLAURA2 and emerging post-progression data inform sequencing decisions.
Advertisement
Episodes in this series
Heather Wakelee, MD, and Helena Yu, MD, discuss how findings from FLAURA2 (NCT04035486), including subsequent therapy outcomes, are influencing clinical decision-making. They consider whether post-progression outcomes are reassuring and how early exposure to chemotherapy may impact later treatment options. The discussion also addresses whether upfront intensification has shifted clinical comfort and raises the question of potential overtreatment in certain patient populations.
Advertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5